Romosozumab-aqqg 89.7 mg/ML [Evenity]
RxNorm 2123187

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2123187 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: romosozumab-aqqg 89.7 mg/ML [Evenity].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDC
Romosozumab-aqqg 89.7 mg/ML [Evenity]
AUI:10896910
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDCPrescribable

Semantic Branded Drug Component (SBDC):
Romosozumab-aqqg 89.7 mg/ML [Evenity]
(Atom ID: 10896910)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
romosozumab-aqqg 89.7 MG/ML [Evenity]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2123187
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
10896910
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDC
Semantic Branded Drug Component (Ingredient + Strength + Brand Name)
Source Code
2123187
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Romosozumab-aqqg Injection


Romosozumab-aqqg injection is used to treat osteoporosis (condition in which the bones become thin and weak and break easily) in postmenopausal women (women who have experienced a change of life; end of menstrual periods) who have a high risk of a fracture or when other osteoporosis treatments did not help or could not be tolerated. Romosozumab-aqqg injection is in a class of medications called monoclonal antibodies. It works by increasing bone formation and decreasing bone breakdown.
[Learn More]


* Please review the disclaimer below.